NCT05430217

Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

Double-blind Placebo-controlled Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg (JSC Valenta Pharm, Russia) in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 268 (actual)
• Sponsor: Valenta Pharm JSC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Study to evaluate the efficacy and safety of Buspirone, sustained-release tablets, 15 mg in patients with autonomic dysfunction syndrome accompanied by vertigo

Conditions

• Vertigo
• Autonomic Dysfunction

Interventions

Type	Name	Description
DRUG	Buspirone	1 tablet (15 mg) once per day for 28 days
DRUG	Placebo	1 placebo tablet once per day for 28 days

Timeline

• Start date: 2022-01-28
• Primary completion: 2022-05-09
• Completion: 2022-05-09
• First posted: 2022-06-24
• Last updated: 2022-06-24

Locations

8 sites across 1 country: Russia